髄膜炎菌感染症ワクチンの世界市場レポート 2025年

髄膜炎菌感染症ワクチン市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は10.0％で、38億3,000万米ドルに成長します。予測期間に予測される成長は、予防医療に対する意識の高まり、対象年齢層の拡大、新規市場参入企業の参入、潜在的な感染症発生に備えた政府や保健機関による備蓄の取り組み、一般市民に対する教育活動の活発化などに起因すると考えられます。この期間に予想される主な動向としては、ワクチン技術の発展、多価ワクチン、結合型ワクチン、タンパク質ベースのワクチンの開発、旅行や移住の世界的動向、mRNA技術の研究開発の増加、耐熱性ワクチン製剤の革新などが挙げられます。

髄膜炎菌感染症ワクチン市場の成長を牽引しているのは、政府による予防接種プログラムの増加です。これらのプログラムは、感染症から人々を守るために無料または手ごろな価格でワクチンを提供する公衆衛生の取り組みです。こうしたプログラムの拡大は、疾病予防に重点を置き、予防接種の普及を通じて医療システムの負担を軽減することに起因しています。ワクチンへのアクセスを向上させ、予防接種率を高めることで、これらのプログラムは人々の意識を高め、疾病発生率を低下させる。また、予防接種の義務化や公衆衛生キャンペーンを通じて需要を喚起することもできます。例えば、2024年4月、米国を拠点とする専門機関である汎米保健機構（PAHO）は、「未来を守るために今行動を起こそう。GetVax（ワクチン接種を受けよう）」というテーマの下、第22回 Vaccination Week in the Americas（VWA）を開始しました。このキャンペーンは、6,500万回分以上のワクチン接種を実施することで、特にワクチン接種が行き届いていない地域におけるワクチン接種率の向上を目指しました。その結果、政府による予防接種の取り組みが拡大し、髄膜炎菌感染症ワクチン市場の拡大に拍車をかけています。

髄膜炎菌感染症ワクチン市場の新興国市場は、血清群防御の拡大、接種スケジュールの簡素化、疾病予防の強化を目的として、5価製剤などの先進ワクチンの開発に注力しています。5価髄膜炎菌ワクチンは、1回の接種で髄膜炎菌の5つの主要な血清群に対する免疫を提供し、複数回の注射の必要性を最小限に抑え、ワクチンコンプライアンスを向上させます。例えば、2023年10月、米国のバイオ製薬会社Pfizer Inc.は、10～25歳の髄膜炎菌感染症予防のために承認された最初で唯一のワクチンであるPENBRAYAのFDA承認を取得しました。この画期的なワクチンは、既存の2つのワクチン、TrumenbaとNimenrixの要素を統合したもので、侵襲性髄膜炎菌感染症（IMD）の世界の症例の大部分を占める髄膜炎菌の最も一般的な5つの血清群（A、B、C、W、Y）を予防します。PENBRAYAは、米国で入手可能なワクチンの中で最も広い血清群をカバーし、完全防御に必要な総投与回数を減らす可能性があることから、疾病予防における大きな飛躍を意味します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の髄膜炎菌感染症ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の髄膜炎菌感染症ワクチン市場：成長率分析
• 世界の髄膜炎菌感染症ワクチン市場の実績：規模と成長, 2019-2024
• 世界の髄膜炎菌感染症ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の髄膜炎菌感染症ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の髄膜炎菌感染症ワクチン市場：ワクチンタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 結合型ワクチン
• 多糖体ワクチン
• 組換えワクチン
• 弱毒生ワクチン
• 世界の髄膜炎菌感染症ワクチン市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳児
• 子供
• 成人
• 高齢者
• 世界の髄膜炎菌感染症ワクチン市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防ワクチン接種
• 曝露後予防
• 旅行関連ワクチン接種
• アウトブレイク対応
• 世界の髄膜炎菌感染症ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の髄膜炎菌感染症ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 家庭
• その他
• 世界の髄膜炎菌感染症ワクチン市場：結合型ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一価
• 四価
• 小児用
• 青年期/成人用
• 世界の髄膜炎菌感染症ワクチン市場：多糖体ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二価
• 三価
• 四価
• 年齢特異的
• 世界の髄膜炎菌感染症ワクチン市場：組換えワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清群B
• 多成分
• 外膜小胞（OMV）ベース
• 世界の髄膜炎菌感染症ワクチン市場：弱毒生ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 実験的経鼻
• 遺伝子組換え
• 混合

第7章 地域別・国別分析

• 世界の髄膜炎菌感染症ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の髄膜炎菌感染症ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 髄膜炎菌感染症ワクチン市場：競合情勢
• 髄膜炎菌感染症ワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corporation Limited
• Serum Institute of India Pvt. Ltd.
• Walvax Biotechnology Co. Ltd.
• Incepta Pharmaceuticals Ltd.
• CanSino Biologics Inc.
• EuBiologics Co. Ltd.
• Biovac Institute
• Shantha Biotech
• Bio-Manguinhos
• Biomed Pvt. Ltd.
• Chengdu Kanghua Biological Products Co. Ltd.
• Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
• Finlay Institute of Vaccines
• Immunopreparat

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 髄膜炎菌感染症ワクチン市場2029：新たな機会を提供する国
• 髄膜炎菌感染症ワクチン市場2029：新たな機会を提供するセグメント
• 髄膜炎菌感染症ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The meningococcal disease vaccine is designed to protect against meningococcal disease, a severe bacterial infection caused by Neisseria meningitidis. This illness can result in meningitis, which is the inflammation of the membranes surrounding the brain and spinal cord, as well as septicemia, a serious bloodstream infection both of which can be life-threatening.

There are several main types of meningococcal vaccines conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines work by linking bacterial sugars to proteins, thereby enhancing the immune response and providing effective protection against serogroups A, C, W, and Y. These vaccines are particularly recommended for adolescents and individuals at higher risk. They are available for a range of age groups, including infants, children, adults, and the elderly, and are used for various purposes such as routine prevention, post-exposure prophylaxis, travel immunization, and in response to outbreaks. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end-users comprising hospitals, specialty clinics, home care services, and additional healthcare settings.

The meningococcal disease vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal disease vaccines market statistics, including the meningococcal disease vaccines industry global market size, regional shares, competitors with the meningococcal disease vaccines market share, detailed meningococcal disease vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the meningococcal disease vaccines industry. This meningococcal disease vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The meningococcal disease vaccine market size has grown rapidly in recent years. It will grow from$2.37 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to enhanced vaccine manufacturing capabilities, the establishment of global health partnerships, incorporation into national immunization programs, an increase in meningococcal disease cases, and intensified efforts by various organizations.

The meningococcal disease vaccine market size is expected to see rapid growth in the next few years. It will grow to$3.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth projected for the forecast period can be attributed to rising awareness of preventive healthcare, the expansion of target age groups, the entry of new market participants, stockpiling initiatives by governments and health agencies in preparation for potential outbreaks, and increasing public education efforts. Key trends expected during this period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global trends in travel and migration, increased research and development in mRNA technology, and innovations in thermostable vaccine formulations.

The growth of the meningococcal disease vaccine market is being driven by the rise in government immunization programs. These programs are public health initiatives that provide free or affordable vaccines to protect populations against infectious diseases. The expansion of these programs stems from a stronger focus on disease prevention and reducing the burden on healthcare systems through widespread vaccination efforts. By increasing access to vaccines and boosting immunization rates, these programs help raise public awareness and lower disease incidence. They also generate demand through vaccination mandates and public health campaigns. For example, in April 2024, the Pan American Health Organization (PAHO), a US-based specialized agency, launched the 22nd Vaccination Week in the Americas (VWA) under the theme "Engage now to protect your future. GetVax." The campaign aimed to boost vaccine coverage, particularly in underserved communities, by administering over 65 million doses. The initiative targeted misinformation and improved vaccine access through community outreach and customized campaigns. As a result, growing government immunization efforts are fueling the expansion of the meningococcal disease vaccine market.

Leading players in the meningococcal disease vaccine market are focusing on the development of advanced vaccines, such as pentavalent formulations, to broaden serogroup protection, simplify vaccination schedules, and enhance disease prevention. A pentavalent meningococcal vaccine offers immunization against five major serogroups of Neisseria meningitidis in a single dose, minimizing the need for multiple injections and improving vaccine compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical firm, received FDA approval for PENBRAYA, the first and only vaccine approved for preventing meningococcal disease in individuals aged 10 to 25 years. This groundbreaking vaccine merges elements from two existing vaccines, Trumenba and Nimenrix, to safeguard against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis, which are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA marks a major leap in disease prevention by offering the widest serogroup coverage among U.S.-available vaccines and potentially reducing the total number of required doses for complete protection.

In September 2023, Biovac, a biopharmaceutical company based in South Africa, joined forces with EuBiologics Co. Ltd. to enhance Africa's capacity for vaccine innovation and self-reliance. This collaboration is focused on technology transfer and the local production of a pentavalent meningococcal conjugate vaccine in Africa. The initiative seeks to meet urgent healthcare demands in the meningitis belt and promote regional vaccine manufacturing capabilities. EuBiologics Co., Ltd., based in South Korea, specializes in the production of pentavalent meningococcal conjugate vaccines.

Major players in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, and Immunopreparat.

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in meningococcal disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the meningococcal disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Meningococcal Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The meningococcal disease vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Conjugate Vaccines; Polysaccharide Vaccines; Recombinant Vaccines; Live Attenuated Vaccines
• 2) By Age Group: Infants; Children; Adults; Older Adults
• 3) By Indication: Preventive Vaccination; Post-Exposure Prophylaxis; Travel-Related Vaccination; Outbreak Response
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Conjugate Vaccines: Monovalent Conjugate Vaccines; Quadrivalent Conjugate Vaccines; Pediatric Conjugate Vaccines; Adolescent Or Adult Conjugate Vaccines
• 2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines; Trivalent Polysaccharide Vaccines; Quadrivalent Polysaccharide Vaccines; Age-Specific Polysaccharide Formulations
• 3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines; Multicomponent Recombinant Vaccines; Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
• 4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines; Genetically Engineered Attenuated Strain Vaccines; Combined Live Attenuated Vaccines
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Meningococcal Disease Vaccine Market Characteristics

3. Meningococcal Disease Vaccine Market Trends And Strategies

4. Meningococcal Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Meningococcal Disease Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Meningococcal Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Meningococcal Disease Vaccine Market Growth Rate Analysis
• 5.4. Global Meningococcal Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Meningococcal Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Meningococcal Disease Vaccine Total Addressable Market (TAM)

6. Meningococcal Disease Vaccine Market Segmentation

• 6.1. Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conjugate Vaccines
• Polysaccharide Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines
• 6.2. Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adults
• Older Adults
• 6.3. Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Vaccination
• Post-Exposure Prophylaxis
• Travel-Related Vaccination
• Outbreak Response
• 6.4. Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent Conjugate Vaccines
• Quadrivalent Conjugate Vaccines
• Pediatric Conjugate Vaccines
• Adolescent Or Adult Conjugate Vaccines
• 6.7. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bivalent Polysaccharide Vaccines
• Trivalent Polysaccharide Vaccines
• Quadrivalent Polysaccharide Vaccines
• Age-Specific Polysaccharide Formulations
• 6.8. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serogroup B Recombinant Protein Vaccines
• Multicomponent Recombinant Vaccines
• Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
• 6.9. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Experimental Intranasal Live Attenuated Vaccines
• Genetically Engineered Attenuated Strain Vaccines
• Combined Live Attenuated Vaccines

7. Meningococcal Disease Vaccine Market Regional And Country Analysis

• 7.1. Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Meningococcal Disease Vaccine Market

• 8.1. Asia-Pacific Meningococcal Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Meningococcal Disease Vaccine Market

• 9.1. China Meningococcal Disease Vaccine Market Overview
• 9.2. China Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Meningococcal Disease Vaccine Market

• 10.1. India Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Meningococcal Disease Vaccine Market

• 11.1. Japan Meningococcal Disease Vaccine Market Overview
• 11.2. Japan Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Meningococcal Disease Vaccine Market

• 12.1. Australia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Meningococcal Disease Vaccine Market

• 13.1. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Meningococcal Disease Vaccine Market

• 14.1. South Korea Meningococcal Disease Vaccine Market Overview
• 14.2. South Korea Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Meningococcal Disease Vaccine Market

• 15.1. Western Europe Meningococcal Disease Vaccine Market Overview
• 15.2. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Meningococcal Disease Vaccine Market

• 16.1. UK Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Meningococcal Disease Vaccine Market

• 17.1. Germany Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Meningococcal Disease Vaccine Market

• 18.1. France Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Meningococcal Disease Vaccine Market

• 19.1. Italy Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Meningococcal Disease Vaccine Market

• 20.1. Spain Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Meningococcal Disease Vaccine Market

• 21.1. Eastern Europe Meningococcal Disease Vaccine Market Overview
• 21.2. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Meningococcal Disease Vaccine Market

• 22.1. Russia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Meningococcal Disease Vaccine Market

• 23.1. North America Meningococcal Disease Vaccine Market Overview
• 23.2. North America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Meningococcal Disease Vaccine Market

• 24.1. USA Meningococcal Disease Vaccine Market Overview
• 24.2. USA Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Meningococcal Disease Vaccine Market

• 25.1. Canada Meningococcal Disease Vaccine Market Overview
• 25.2. Canada Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Meningococcal Disease Vaccine Market

• 26.1. South America Meningococcal Disease Vaccine Market Overview
• 26.2. South America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Meningococcal Disease Vaccine Market

• 27.1. Brazil Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Meningococcal Disease Vaccine Market

• 28.1. Middle East Meningococcal Disease Vaccine Market Overview
• 28.2. Middle East Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Meningococcal Disease Vaccine Market

• 29.1. Africa Meningococcal Disease Vaccine Market Overview
• 29.2. Africa Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Meningococcal Disease Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Meningococcal Disease Vaccine Market Competitive Landscape
• 30.2. Meningococcal Disease Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Meningococcal Disease Vaccine Market Other Major And Innovative Companies

• 31.1. Hualan Biological Engineering Inc.
• 31.2. Beijing Tiantan Biological Products Corporation Limited
• 31.3. Serum Institute of India Pvt. Ltd.
• 31.4. Walvax Biotechnology Co. Ltd.
• 31.5. Incepta Pharmaceuticals Ltd.
• 31.6. CanSino Biologics Inc.
• 31.7. EuBiologics Co. Ltd.
• 31.8. Biovac Institute
• 31.9. Shantha Biotech
• 31.10. Bio-Manguinhos
• 31.11. Biomed Pvt. Ltd.
• 31.12. Chengdu Kanghua Biological Products Co. Ltd.
• 31.13. Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
• 31.14. Finlay Institute of Vaccines
• 31.15. Immunopreparat

32. Global Meningococcal Disease Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Meningococcal Disease Vaccine Market

34. Recent Developments In The Meningococcal Disease Vaccine Market

35. Meningococcal Disease Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Meningococcal Disease Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Meningococcal Disease Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Meningococcal Disease Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer